Literature DB >> 22418890

The impact of bariatric surgery on nonalcoholic steatohepatitis.

Charlotte Rabl1, Guilherme M Campos.   

Abstract

Nonalcoholic steatohepatitis (NASH) is a stage of nonalcoholic fatty liver disease (NAFLD), and in most patients, is associated with obesity and the metabolic syndrome. The current best treatment of NAFLD and NASH is weight reduction with the current options being life style modifications, with or without pharmaceuticals, and bariatric surgery. Bariatric surgery is an effective treatment option for individuals who are severely obese (body mass index ≥ 35 kg/m(2)), and provides for long-term weight loss and resolution of obesity-associated diseases in most patients. Regression and/or histologic improvement of NASH have been documented after bariatric surgery. We review the available literature reporting on the impact of the various bariatric surgery techniques on NASH. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22418890     DOI: 10.1055/s-0032-1306428

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  22 in total

1.  Changes in post-prandial glucose and pancreatic hormones, and steady-state insulin and free fatty acids after gastric bypass surgery.

Authors:  Guilherme M Campos; Charlotte Rabl; Peter J Havel; Madhu Rao; Jean-Marc Schwarz; Morris Schambelan; Kathleen Mulligan
Journal:  Surg Obes Relat Dis       Date:  2013-07-20       Impact factor: 4.734

2.  The Role of Bariatric Surgery in the Management of Nonalcoholic Steatohepatitis.

Authors:  Joseph K Lim
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-06

3.  Indications for Surgery for Obesity and Weight-Related Diseases: Position Statements from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO).

Authors:  Maurizio De Luca; Luigi Angrisani; Jacques Himpens; Luca Busetto; Nicola Scopinaro; Rudolf Weiner; Alberto Sartori; Christine Stier; Muffazal Lakdawala; Aparna G Bhasker; Henry Buchwald; John Dixon; Sonja Chiappetta; Hans-Christian Kolberg; Gema Frühbeck; David B Sarwer; Michel Suter; Emanuele Soricelli; Mattias Blüher; Ramon Vilallonga; Arya Sharma; Scott Shikora
Journal:  Obes Surg       Date:  2016-08       Impact factor: 4.129

4.  Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.

Authors:  Thuy-Anh Le; Rohit Loomba
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

5.  Nonalcoholic fatty liver disease and gastric bypass surgery regulate serum and hepatic levels of pyruvate kinase isoenzyme M2.

Authors:  Luca Meoli; Nitin K Gupta; Nima Saeidi; Courtney A Panciotti; Sudha B Biddinger; Kathleen E Corey; Nicholas Stylopoulos
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-02-20       Impact factor: 4.310

6.  Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.

Authors:  Jennifer A Flemming; W Ray Kim; Carol L Brosgart; Norah A Terrault
Journal:  Hepatology       Date:  2016-12-24       Impact factor: 17.425

7.  Functional Liver Recovery After Bariatric Surgery--a Prospective Cohort Study with the LiMAx Test.

Authors:  Patrick H Alizai; Janica Wendl; Anjali A Roeth; Christian D Klink; Tom Luedde; Inga Steinhoff; Ulf P Neumann; Maximilian Schmeding; Florian Ulmer
Journal:  Obes Surg       Date:  2015-11       Impact factor: 4.129

Review 8.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

9.  Simultaneous living donor liver transplant with sleeve gastrectomy for metabolic syndrome and NASH-related ESLD-First report from India.

Authors:  Suneed Kumar; Nidhi Khandelwal; Abhaya Kumar; Kapildev Yadav; Swapnil Sharma; Shailesh Sable; Ashutosh Chauhan; Sorabh Kapoor; Vibha Varma; Jaydeep Palep; Vinay Kumaran
Journal:  Indian J Gastroenterol       Date:  2017-05-31

Review 10.  Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.

Authors:  Ye Liu; Rui Wei; Tian-Pei Hong
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.